Yagami Co., Ltd. FY2026 Analysis: Strong Profit Growth Driven by Operational Efficiency

Yagami Co., Ltd. FY2026 Analysis: Strong Profit Growth Driven by Operational Efficiency

Yagami Co., Ltd. (TSE:7488), a key supplier of scientific and medical equipment, particularly strong in the school market, reported robust financial results for its full year (FY) ending April 2026. The company achieved significant year-over-year (YoY) growth in profitability, with Net Profit rising by 22.1%, despite a more moderate increase in top-line revenue.

Yagami Co., Ltd. specializes in distributing scientific and medical equipment, maintaining a leading position within the school sector. Its product portfolio includes Automated External Defibrillator (AED) sales and the manufacturing of sterilizers.

The financial results indicate a clear decoupling of revenue growth from profit growth. While Revenue grew by 5.8% YoY, Operating Profit increased by 14.8%, and Net Profit saw an even stronger increase of 22.1% YoY. The Operating Margin of 19.4% highlights the company’s ability to maintain a highly profitable operational structure, significantly exceeding typical industry benchmarks. The disproportionately large jump in Net Profit suggests exceptional efficiency in managing cost of goods sold and selling, general, and administrative expenses, or potentially significant non-operating income contributions.

Strategically, the company benefits from a stable foundation provided by the school market, where demand for equipment like practical training stations and storage cabinets is underpinned by the “annualization of construction periods” (工期の通年化). Furthermore, the medical device segment shows diversification; while school equipment sales remained steady, AED sales saw notable growth, particularly in the private sector. The robust performance of sterilizer sales in Asian markets, bolstered by the weaker yen, confirms the functionality of its global sales channels.

The balance sheet strength is a key highlight, with the Equity Ratio reaching 77.0%, signaling an extremely high degree of financial stability and resilience against potential market volatility or future capital expenditure requirements.

Next Year Guidance

The full-year forecast for FY2027 shows projections for Revenue, Operating Profit, Ordinary Income, and Net Profit all below the respective FY2026 actual figures. This suggests a generally conservative outlook for the coming fiscal year.

What to Watch

Investors should monitor the continued diversification of revenue streams, particularly the growth trajectory of AED sales in the private sector and the sustained demand for sterilizers in Asia. Secondly, while the high Equity Ratio provides a strong buffer, the market will be keenly watching the reasons behind the conservative FY2027 guidance, which suggests caution regarding near-term market headwinds. Finally, international investors should pay close attention to the accounting treatment regarding the full subsidiaryization of Heiyama Seizo, as the composition of Net Profit can be influenced by structural accounting changes rather than purely organic business performance.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.